SLC5A2 and congestive heart failure: Background: Dapagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, has been shown to improve prognosis in patients with chronic heart failure (CHF), in whom a transient decline in the estimated glomerular filtration rate (eGFR), known as the “initial dip,” is often observed within the first 1–2 weeks of SGLT2 inhibitor therapy.